





Article

The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study

Elfrid Christine Smith Sandvik ¹, Kristin Matre Aasarød ^{1,2}, Gjermund Johnsen ^{3,4}, Dag Arne Lihaug Hoff ^{1,5}, Bård Kulseng ³, Åsne Ask Hyldmo ⁴, Hallvard Græslie ⁶, Siren Nymo ^{1,3,6}, Jorunn Sandvik ^{3,4,7}  and Reidar Fossmark ^{1,2,*} 

- ¹ Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
 - ² Department of Gastroenterology and Hepatology, St. Olav's University Hospital, 7006 Trondheim, Norway
 - ³ Obesity Research Group, Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
 - ⁴ Centre for Obesity and Innovation (ObeCe), Clinic of Surgery, St. Olav's University Hospital, 7006 Trondheim, Norway
 - ⁵ Department of Medicine, Møre and Romsdal Hospital Trust, 6026 Ålesund, Norway
 - ⁶ Nord-Trøndelag Hospital Trust, Clinic of Surgery, Namsos Hospital, 7800 Namsos, Norway
 - ⁷ Department of Surgery, Møre and Romsdal Hospital Trust, 6026 Ålesund, Norway
- * Correspondence: reidar.fossmark@ntnu.no



Citation: Sandvik, E.C.S.; Aasarød, K.M.; Johnsen, G.; Hoff, D.A.L.; Kulseng, B.; Hyldmo, Å.A.; Græslie, H.; Nymo, S.; Sandvik, J.; Fossmark, R. The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study. *J. Clin. Med.* **2022**, *11*, 4910. <https://doi.org/10.3390/jcm11164910>

Academic Editors: Hirayuki Enomoto and Tatsuo Kanda

Received: 28 July 2022

Accepted: 18 August 2022

Published: 21 August 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated by RYGB in Central Norway were analysed. Variables incorporated in NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4) index and anthropometric data were collected before surgery and a mean of 11.6 years postoperatively. FIB-4 > 1.3 or NFS > 0.675 were used as cut-off values for advanced fibrosis. Proportions with advanced fibrosis decreased from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% using NFS, with resolution rates of advanced fibrosis of 42% and 73%, respectively. The shift towards lower fibrosis categories was significant (NFS $p < 0.0001$; FIB-4 $p = 0.002$). NFS decreased from -1.32 (IQR -2.33 – -0.39) to -1.71 (IQR -2.49 – -0.95 , $p < 0.001$) 11.6 years after surgery, whereas FIB-4 did not change: 0.81 (IQR 0.59–1.25) to 0.89 (IQR 0.69–1.16, $p = 0.556$). There were weak correlations between change in fibrosis scores and weight loss. In conclusion, the majority of patients with advanced fibrosis at baseline had improvement after 11.6 years. Factors associated with reduction in fibrosis were not identified.

Keywords: NAFLD; Roux-en-Y gastric bypass; liver fibrosis; FIB-4; NAFLD Fibrosis index; non-invasive fibrosis scores; obesity

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver. The diagnosis represents a range of different stages of chronic liver disease, including non-alcoholic steatohepatitis (NASH), a more severe form with a significant risk of cirrhosis development. NAFLD is defined by the presence of steatosis in >5% of hepatocytes and requires secondary causes including excessive alcohol consumption (>30 g/d for men, >20 g/d for women) to be ruled out [1]. In the Western world, NAFLD is now the most frequent cause of chronic liver disease [2] with a global prevalence estimated to 25% [3]. A study based on data from the Nord-Trøndelag Health Study (HUNT) using the Fatty Liver Index found a prevalence of 36% [4]. It is predicted that cirrhosis caused by NAFLD will be the most common indication for liver transplantation in several Western countries

within 2030 [2], Nordic countries included [5]. NAFLD is associated with overweight and obesity [6], as well as metabolic syndrome and type 2 diabetes mellitus (T2DM) [2]. Clinical symptoms of NAFLD are seldom present before cirrhosis develops. The condition is underdiagnosed since up to 80% of patients with NAFLD also have normal liver enzyme values [7]. Few isolated biochemical parameters have a satisfactory sensitivity and specificity in detecting NAFLD, NASH and fibrosis [8]. However, combining variables into mathematical algorithms provides a higher prediction accuracy. Although histological examination of a liver biopsy is the gold standard for classifying NAFLD, NASH and fibrosis, non-invasive methods such as ultrasound (US), computer tomography (CT) and magnetic resonance imaging (MRI) are increasingly being used [1]. Alternative tools are biomarkers alone or combined with anthropometric variables and the presence of associated diseases. Several scoring systems and biomarker panels have been developed and validated for this purpose [9]. The Fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) have both been compared to US elastography and liver histology [9]. The use of these scores is recommended in patients with low-risk of advanced fibrosis/cirrhosis by the Clinical Practice Guidelines for the management of NAFLD developed by European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) [1].

Patients with NAFLD have an increased overall mortality risk, in particular due to cardiovascular disease and liver-related events including hepatocellular carcinoma [10]. The first-line treatment is lifestyle changes. However, weight loss of 7–10% seems necessary to induce regression of NASH [11]. People with severe obesity 18–60 years of age, who are not able to attain this weight loss, may be eligible for bariatric surgery such as Roux-en-Y gastric bypass (RYGB). In addition to long-term weight reduction, RYGB also aims to reduce associated comorbidities, especially metabolic syndrome and T2DM, with a subsequent decreased risk of cardiovascular events and mortality [11], as well as increase quality of life. Several studies have demonstrated short- and mid-term beneficial effects of RYGB on NAFLD [12,13]; however, long-term data are scarce. This study aimed to examine the effect of RYGB on NAFLD fibrosis assessed by FIB-4 and NFS more than a decade after surgery. Furthermore, the study aimed to identify characteristics of patients with resolution of fibrosis.

2. Materials and Methods

2.1. Study Design

The study was a retrospective analysis of data collected as a part of the Bariatric Surgery Observation Study (BAROBS). BAROBS is a follow-up study of patients operated for severe obesity with RYGB between 2003 and 2009 at three public hospitals in Central Norway Regional Health Authority (Helse Midt-Norge). The objective of the BAROBS study was to evaluate the long-term effects of RYGB on weight loss, comorbidities associated with obesity as well as quality of life and overall health. The patients were invited to a follow-up visit between 2018 and 2020, and 546 patients (58.7%) of the 930 who underwent RYGB in the period participated. Sixteen patients had RYGB as a secondary bariatric procedure, leaving 530 patients with RYGB as their primary bariatric procedure. The data set consists of laboratory tests and anthropometric data collected before surgery and in conjunction with the follow-up visit, in addition to information from the patients' preoperative medical records, a self-administered questionnaire and an interview with a physician the day of the BAROBS follow-up.

2.2. Criteria for Surgery

The criteria for being approved for RYGB surgery were in accordance with the national and international guidelines at the time:

18–60 years of age

Body mass index (BMI) > 40 kg/m² or BMI > 35 kg/m² with obesity related comorbidities, when obesity was not caused by an endocrine disorder

Failed attempts at non-surgical weight loss

No medical or psychological contraindications to surgery, eating disorder, known alcohol or medication abuse or other conditions not compatible with necessary lifestyle changes and follow-up postoperatively.

2.3. Exclusion Criteria

Patients were excluded from this particular study if they had:

- Missing laboratory tests needed to calculate FIB-4 or NFS
- Excessive alcohol consumption defined as >1 unit/d for women, >2 units/d for men [14] and/or disclosing a problem with alcohol abuse postoperatively.

A flowchart of the study population is presented in Figure 1. A strict threshold for excessive alcohol consumption was chosen, as Rehm et.al. found that already one drink per day was associated with a significantly elevated mortality risk [14]. Patients who have undergone bariatric surgery potentially have an increased long-term risk of alcohol-related cirrhosis [15,16] that in part might be due to altered alcohol metabolism [17]. Based on the considerations above, the stricter threshold was chosen to separate the effects of RYGB *per se* and alcohol intake on fibrosis scores.




Figure 1. Flow-chart of the study population.

2.4. Fibrosis Estimation

The NAFLD fibrosis score (NFS) comprises six variables: age, BMI, platelet count, albumin, presence of hyperglycaemia/diabetes and AST/ALT ratio (AAR). Patients were defined as having T2DM if they had been diagnosed with diabetes or had a HbA1c ≥ 48 mmol/mol ($\geq 6.5\%$), according to the national guidelines by the Norwegian Directorate of Health. The Fibrosis-4 (FIB-4) index is composed of the following variables: platelet count, age and levels of ALT and AST. The EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis recommend cut-off values for FIB-4 < 1.3 and NFS < -1.455 to rule out advanced fibrosis in patients with NAFLD [18]. A FIB-4 ≥ 1.3 suggests an intermediate to high risk and should prompt

further investigation with transient elastography (TE) and/or patented serum tests. A NFS > 0.675 indicates the presence of advanced fibrosis [19] and has a high specificity [18]. Based on these recommendations, we used FIB-4 as a dichotomous variable with a cut-off of 1.3 and NFS as a polychotomous variable divided into three groups: <−1.455 low risk, −1.455 to 0.675 intermediate risk and >0.675 high risk.

2.5. Statistical Analysis

Descriptive data are presented as frequency (n (%)) for categorical data and mean ± standard deviation (SD) or median and interquartile range (IQR) for numerical data depending on distribution. Normality was assessed using the Shapiro–Wilk test. The Pearson χ^2 or Fishers exact test were used for comparisons of independent categorical variables between groups and McNemar’s test for paired categorical variables. Comparisons of independent continuous variables between groups were analysed by independent samples Student’s t test for two variables and one-way ANOVA for more than two variables, both when data were normally distributed. Comparisons of independent non-parametric continuous variables were analysed by Mann–Whitney U test for two variables and Kruskal–Wallis test for more than two variables. The paired Wilcoxon’s signed rank test was used to compare FIB-4 and NFS before and after surgery, while paired Student’s t test was used for comparing paired data of continuous variables that were normally distributed. Correlation between weight loss and changes in fibrosis scores was analysed with Pearson or Spearman tests depending on linearity, outliers and type of data (normal or continuous). *p* values < 0.05 were considered statistically significant. All statistical analyses were conducted using IBM SPSS Statistics version 27.0 (IBM Corporation, Armonk, NY, USA).

3. Results

3.1. Patient Characteristics

A total of 220 patients, whereof 172 (78.2%) were female, were included in this study. Median BMI prior to RYGB surgery was 43.5 kg/m² (IQR 40.4–46.9), while median BMI at the time of BAROBS was decreased to 33.1 kg/m² (IQR 29.5–38.1, *p* < 0.001) after a mean follow-up time of 11.6 years (SD ± 1.65). Patient characteristics are summarized in Tables 1 and 2.

Table 1. Study population prior to Roux-en-Y gastric bypass surgery.

Variable Characteristics	Overall (n = 220)	FIB-4			NFS	
		<1.3 (n = 168)	≥1.3 (n = 52)	<−1.455 (n = 100)	Intermediate (n = 101)	>0.675 (n = 19)
Age, years, mean ± SD	40.1 ± 9.5	37.7 ± 8.4	47.6 ± 9.0 *** ^a	36.8 ± 7.8	42.0 ± 9.9	46.6 ± 9.4 *** ^b
Female, n (%)	172 (78.2)	135 (80.4)	37 (71.2) ^a	79 (79.0)	77 (76.2)	16 (84.2) ^b
BMI, kg/m ² , median (IQR)	43.5 (40.4–46.9)	43.7 (40.6–47.4)	43.2 (39.5–45.7) ^a	42.7 (40.3–45.5)	43.8 (40.6–47.4)	45.7 (41.2–51.2) ** ^b
T2DM n (%)	40 (18.2)	28 (16.7)	12 (23.1) ^a	8 (8.0)	27 (26.7)	5 (26.3) ** ^b
Diet controlled	4 (1.8)	3 (1.8)	1 (1.9)	0 (0)	3 (3.0)	1 (5.3)
Oral diabetics	23 (10.5)	14 (8.3)	9 (17.3)	6 (6.0)	14 (13.9)	3 (15.8)
Insulin	11 (5.0)	9 (5.4)	2 (3.8)	2 (2.0)	8 (7.9)	1 (5.3)
AST, U/L, median (IQR)	37.5 (28.0–49.8)	34.0 (27.0–44.0)	53.5 (42.0–71.3) *** ^a	36.0 (27.0–46.0)	38.0 (29.5–47.5)	54.0 (37.0–69.0) ** ^b
ALT, U/L, median (IQR)	34.0 (23.3–50.8)	35.0 (24.5–54.0)	30.5 (19.0–44.8) ^a	38.5 (29.0–60.8)	32.0 (23.0–46.0)	20.0 (18.0–34.0) *** ^b
PLT, ×10 ⁹ /L, median (IQR)	297 (253–349)	311 (268–359)	248 (210–292) *** ^a	341 (301–384)	271 (239–301)	225 (188–286) *** ^b
ALB, g/L, median (IQR)	42.0 (40.0–44.0)	42.0 (40.0–44.0)	42.0 (40.0–44.8) ^a	43.0 (41.0–45.0)	41.0 (39.5–43.5)	41.0 (39.0–43.0) ** ^b

Table 1. Cont.

Variable Characteristics	Overall (n = 220)	FIB-4			NFS	
		<1.3 (n = 168)	≥1.3 (n = 52)	<−1.455 (n = 100)	Intermediate (n = 101)	>0.675 (n = 19)
FIB-4, median (IQR)	0.81 (0.59–1.25)	0.72 (0.55–0.89)	1.61 (1.46–2.07) ^{***,a}	0.62 (0.47–0.79)	0.96 (0.77–1.40)	2.08 (1.56–2.99) ^{***,b}
NFS, median (IQR)	−1.32 (−2.33–−0.39)	−1.74 (−2.51–−1.03)	0.07 (−0.54–0.94) ^{***,a}	−2.40 (−2.81–−1.89)	−0.61 (−1.14–−0.07)	1.17 (0.91–1.71) ^{***,b}

^a Comparison between FIB-4 categories; ^b Comparison between NFS categories; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; FIB-4, Fibrosis-4 index; NFS, non-alcoholic fatty liver disease fibrosis score; BMI, Body Mass Index; T2DM, type 2 diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine transaminase; PLT, blood platelets; ALB, albumin; IQR, interquartile range; SD, standard deviation.

Table 2. Study population 11.6 years after Roux-en-Y gastric bypass surgery.

Variable Characteristics	Overall (n = 220)	FIB-4			NFS	
		<1.3 (n = 189)	≥1.3 (n = 31)	<−1.455 (n = 128)	Intermediate (n = 87)	>0.675 (n = 5)
Age, years, mean ± SD	51.7 ± 9.6	50.2 ± 9.0	60.5 ± 8.6 ^{***,a}	48.8 ± 8.7	55.0 ± 9.3	65.1 ± 10.4 ^b
Female n (%)	172 (78.2)	152 (80.4)	20 (64.5) ^{*,a}	108 (84.4)	60 (69.0)	4 (80.0) ^{*,b}
BMI, kg/m ² , median (IQR)	33.1 (29.5–38.1)	33.1 (29.6–38.4)	32.9 (29.0–36.1) ^a	31.7 (28.5–35.3)	35.8 (31.9–41.0)	36.7 (29.9–49.2) ^{***,b}
BMI nadir, kg/m ² , median (IQR)	28.0 (26.0–31.0)	28.0 (26.0–32.0)	28.0 (26.0–30.0) ^a	27.0 (24.3–29.0)	29.0 (27.0–33.0)	35.0 (30.5–42.0) ^{***,b}
%TWL, mean ± SD	22.8 ± 11.2	22.4 ± 11.4	25.2 ± 9.32 ^a	25.5 ± 10.6	19.0 ± 11.1	19.3 ± 10.3 ^{***,b}
%EWL, mean ± SD	54.5 ± 27.1	53.2 ± 27.5	62.0 ± 24.0 ^a	61.9 ± 26.1	44.0 ± 25.2	47.1 ± 28.2 ^{***,b}
T2DM n (%)	23 (10.5)	18 (9.5)	5 (16.1) ^a	3 (2.3)	17 (19.5)	3 (60.0) ^{***,b}
AST, U/L, median (IQR)	21.0 (17.0–25.0)	20.0 (17.0–24.0)	26.0 (23.0–31.0) ^{***,a}	21.0 (17.0–25.0)	20.0 (18.0–25.0)	21.0 (17.5–31.0) ^b
ALT, U/L, median (IQR)	21.0 (17.0–27.0)	21.0 (17.0–27.0)	22.0 (16.0–31.0) ^a	21.0 (17.0–27.8)	20.0 (16.0–28.0)	21.0 (19.5–25.0) ^b
PLT, ×10 ⁹ /L, median (IQR)	252 (220–301)	265 (225–307)	188 (175–231) ^{***,a}	283 (239–318)	229 (199–252)	176 (149–209) ^{***,b}
ALB, g/L, median (IQR)	44.0 (42.0–45.0)	44.0 (42.0–45.0)	44.0 (42.0–45.0) ^a	44.0 (43.0–45.8)	43.0 (42.0–45.0)	41.0 (39.5–42.5) ^{**b}
FIB-4, median (IQR)	0.89 (0.69–1.16)	0.81 (0.66–1.06)	1.59 (1.48–1.81) ^{***,a}	0.77 (0.60–0.93)	1.14 (0.89–1.35)	2.32 (1.04–2.69) ^{***,b}
NFS, median (IQR)	−1.71 (−2.49–−0.95)	−1.83 (−2.65–−1.23)	−0.50 (−0.99–0.10) ^{***,a}	−2.31 (−2.89–−1.83)	−0.91 (−1.17–−0.50)	1.07 (0.85–1.40) ^{***,b}

^a Comparison between FIB-4 categories; ^b Comparison between NFS categories; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; FIB-4, Fibrosis-4 index; NFS, non-alcoholic fatty liver disease fibrosis score; BMI, body mass index; %TWL, percentage total weight loss; %EWL, percentage excess weight loss; T2DM, type 2 diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine transaminase; PLT, blood platelets; ALB, albumin; IQR, interquartile range; SD = standard deviation.

3.2. Change in NFS and FIB-4 Scores during the Observation Period

The median NFS at baseline was −1.32 (IQR −2.33–−0.39) and decreased to −1.71 (IQR −2.49–−0.95, $p < 0.001$) 11.6 years after RYGB surgery. However, the median FIB-4 score did not change with a median of 0.81 (IQR 0.59–1.25) preoperatively and 0.89 (IQR 0.69–1.16, $p = 0.556$) at follow-up. A comparison of results at baseline and at follow-up is summarized in Table 3.

Table 3. Comparison of NFS, FIB-4 and their components before and 11.6 years after Roux-en-Y gastric bypass surgery.

Characteristics (n = 220)	Before Surgery	11.6 Years after Surgery	p Value
NFS, median (IQR)	−1.32 (−2.33–−0.39)	−1.71 (−2.49–−0.95)	<0.001
FIB-4, median (IQR)	0.81 (0.59–1.25)	0.89 (0.69–1.16)	0.556
BMI, kg/m ² , median (IQR)	43.5 (40.4–46.9)	33.1 (29.5–38.1)	<0.001
T2DM n (%)	40 (18.2)	23 (10.5)	<0.001
AST, U/L, median (IQR)	37.5 (28.0–49.8)	21.0 (17.0–25.0)	<0.001
ALT, U/L, median (IQR)	34.0 (23.3–50.8)	21.0 (17.0–27.0)	<0.001
PLT, ×10 ⁹ /L, median (IQR)	297 (253–349)	252 (220–301)	<0.001
ALB, g/L, median (IQR)	42.0 (40.0–44.0)	44.0 (42.0–45.0)	<0.001

NFS, non-alcoholic fatty liver disease fibrosis score; FIB-4, Fibrosis-4 index; BMI, body mass index; T2DM, type 2 diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine transaminase; PLT, blood platelets; ALB, albumin; IQR, interquartile range; SD, standard deviation.

3.3. Reduction of NFS and FIB-4 in High-Risk Patients

Nineteen patients (8.6%) had a preoperative high risk of NAFLD-related fibrosis according to NFS compared to five (2.3%) patients 11.6 years after surgery. There was a significant overall shift towards lower risk categories ($p < 0.0001$) (Figure 2). Three out of the five patients with a high postoperative risk moved from the intermediate- to high-risk group, whereas two patients had a persistent high risk. Fifty-two (24%) patients had an elevated risk of fibrosis according to the FIB-4 index at baseline compared to 31 (14%) patients 11.6 years after surgery. The shift towards lower risk categories was significant ($p = 0.002$). Eleven out of the 31 patients (35%) experienced an increased risk postoperatively, moving from the low- to high-risk group, whereas the remaining 20 (65%) patients had a persistent elevated risk.




Figure 2. Risk distribution according to NAFLD fibrosis Score (A) and Fibrosis-4 index (B) before and 11.6 years after Roux-en-Y gastric bypass.

3.4. Correlation between Changes in NFS and FIB-4, Weight Loss and Remission of Type 2 Diabetes Mellitus

There was a strong correlation between changes in NFS and FIB-4 ($r = 0.658, p < 0.0001$) (Figure 3A). There was no correlation between change in FIB-4 and weight loss variables (%EWL ($r = 0.111, p = 0.100$) and %TWL ($r = 0.110, p = 0.104$)) and only a weak negative correlation between the decrease in NFS and weight loss (%EWL ($r = -0.251, p < 0.0001$) and %TWL ($r = -0.280, p < 0.0001$)). Similarly, there was no correlation between change in FIB-4 ($r = -0.092, p = 0.172$) and change in T2DM status, and the correlation between change in T2DM and change in NFS was weak but significant ($r = 0.203, p = 0.003$).





Figure 3. Cont.



(C)

Figure 3. Scatterplots illustrating the correlations between change in NAFLD Fibrosis Score (NFS) and FIB-4 index (A) and between %total weight loss and FIB-4 (B) and NFS (C) following Roux-en-Y gastric bypass surgery. FIB-4, Fibrosis-4 index; NFS, non-alcoholic fatty liver disease fibrosis score; %TWL, percentage total weight loss.

3.5. Characteristics of Patients with Elevated Fibrosis Risk at Baseline and Subsequent Improvement

To assess characteristics of patients who seemed to benefit more from RYGB surgery in terms of fibrosis reduction, we performed a sub-analysis of patients with a high risk of fibrosis (FIB-4 \geq 1.3) at baseline and compared patients with reduction versus no reduction in fibrosis scores 11.6 years after RYGB surgery. Patients with a fibrosis risk-reduction (FIB-4 < 1.3) and the group with persistent elevated risk (FIB-4 \geq 1.3) did not differ in terms of age, sex, BMI, weight loss or T2DM prevalence (Table 4). An equivalent analysis of the patients with a baseline NFS > 0.675 was omitted due to small sample size (16 vs. 3 patients).

Table 4. Patients with FIB-4 \geq 1.3 at baseline with improvement in FIB-4 index vs. patients without improvement.

Variable	FIB-4 < 1.3 (n = 32)	FIB-4 \geq 1.3 (n = 20)	p Value
Age baseline, years, mean \pm SD	45.9 \pm 9.33	50.2 \pm 7.84	0.099
Female n (%)	25 (78.1)	12 (60.0)	0.213
BMI baseline, kg/m ² , median (IQR)	43.1 (39.5–45.8)	44.1 (39.3–45.6)	0.821
BMI follow-up, kg/m ² , median (IQR)	33.1 (28.8–37.0)	31.9 (28.2–36.6)	0.529
BMI nadir, kg/m ² , median (IQR)	28.0 (25.0–32.0)	28.0 (25.5–33.0)	0.741
%TWL, mean \pm SD	21.7 \pm 11.8	26.8 \pm 9.55	0.108
%EWL, mean \pm SD	53.1 \pm 28.7	66.1 \pm 24.9	0.101
T2DM baseline, n (%)	9 (28.1)	3 (15.0)	0.330
T2DM follow-up, n (%)	6 (18.8)	2 (10.0)	0.463

FIB-4, Fibrosis-4 index; BMI, body mass index; %TWL, percentage total weight loss; %EWL, percentage excess weight loss; T2DM, type 2 diabetes mellitus; IQR, interquartile range; SD, standard deviation.

We conducted a similar analysis of the whole population ($n = 220$), comparing patients with a reduction in fibrosis scores with patients with an increase, using scores as continuous variables. According to FIB-4, patients with an increased score at follow-up had a greater weight loss with %EWL 57.8 ± 26.1 vs. 50.2 ± 28.0 ($p = 0.039$) and %TWL 24.4 ± 10.6 vs. 20.7 ± 11.6 ($p = 0.016$) in the group with an increased score versus the group with a decreased score, respectively (Table A1 in Appendix A). The patients with an increased NFS at follow-up experienced less weight loss with %EWL 49.2 ± 28.5 vs. 57.6 ± 25.9 ($p = 0.026$) and %TWL 20.2 ± 11.5 vs. 24.3 ± 10.7 ($p = 0.008$) in the group with an increased score versus the group with a decreased score, respectively (Appendix A, Table A1).

4. Discussion

We found that RYGB surgery led to a significant reduction of liver fibrosis risk assessed by the non-invasive FIB-4 index and NFS 11.6 years postoperatively, although the improvement of FIB-4 was significant only when assessed as a dichotomous variable. The proportion of patients with advanced fibrosis was reduced from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% assessed by NFS, implying resolution rates for advanced fibrosis of 42% and 73%, respectively. The above-mentioned reductions in fibrosis scores were observed despite age being a component in both scores and a mean 11.6-year follow-up time. The NFS and FIB-4 index were developed in studies where most patients were between the age of 35 and 65 [20]. Age has later been identified as a confounding factor for NFS and FIB-4 in diagnosing advanced fibrosis since the scores overestimate the risk of fibrosis in individuals >65 years of age [20]. A higher cut-off for ruling out advanced fibrosis in patients >65 years has therefore been proposed (2.0 for FIB-4 and 0.12 for NFS); however, further validation studies seem necessary before age-dependent cut-off values can be used in clinical practice. For patients ≤ 35 years, the overall performance of both scores is also poor [20]. In our study population, 74 vs. 5 patients were ≤ 35 years and 0 vs. 20 patients were >60 years at baseline vs. 11.6 years later, respectively. The prevalence of biopsy-proven fibrosis in obese patients has been reported in the range of 25–47%, also including patients undergoing bariatric surgery [21–24]. In the current study, the prevalence of fibrosis assessed by NFS and FIB-4 was found to be lower (8.6–24%). A high proportion of young patients at baseline might contribute to a lower prevalence of advanced fibrosis, particularly in women where the risk of fibrosis increases after menopause onset [25]. Two recent meta-analyses have reported that RYGB had a positive effect on NAFLD after short- to mid-term follow-up time of 1–60 months, with improvement or resolution of histological steatosis and steatohepatitis in the majority of patients, as well as resolution of fibrosis in 28–51% [12,13]. Importantly, studies assessing resolution of liver fibrosis after RYGB with NFS and/or FIB-4 have found improvement in agreement with studies using biopsies [26–29]. The proportion of patients with a low postoperative fibrosis score was similar in our population to that in studies with shorter follow-up times [11,12,29–33]. The resolution rates of advanced fibrosis evaluated by NFS have been reported to be 55% [29] and 100%, although in a relatively small study [34], both one year after RYGB. Others have also reported similar proportions of improvement in NFS after one year [35]. However, our findings indicate that the beneficial effects of RYGB on fibrosis persist long term for 11.6 years after surgery.

The exact mechanisms behind improvement of NAFLD-related fibrosis are uncertain. There were only weak (NFS) or non-significant (FIB-4) correlations between change in fibrosis scores and weight loss variables and reduced prevalence of T2DM. Other predictors of improved fibrosis scores could not be identified. Patients with improved FIB-4 actually experienced less weight loss (%TWL and %EWL), while patients with improved NFS experienced greater weight loss, although the latter association should be interpreted with care, since BMI is a component of NFS. This indicates that although weight loss *per se* is important in NAFLD treatment, other pathophysiological mechanisms play a role in fibrosis regression, which is also suggested by two other patient studies [36,37]. These clinical observations are supported by experimental animal studies demonstrating that

improvement of glycemia [38] and reversal of NAFLD after RYGB occurs independent of weight loss [39]. We did not find factors associated with improvement of fibrosis. Perhaps of equal importance is that we did not identify factors associated with lack of improvement or progression. In a clinical setting, this implies that RYGB could be considered in all patients with advanced fibrosis, and RYGB seems to be beneficial and relatively safe in patients with cirrhosis [40].

Strengths of the study include the long follow-up time of a relatively large study population. Limitations of the study include the lack of liver biopsy as a gold standard for evaluation of fibrosis. The study was retrospective, and fibrosis scores could be analysed only in patients with complete data for all score components as illustrated in Figure 1. Furthermore, laboratory tests were taken at different time points within the year before surgery. Various medications used during the study period could potentially affect non-invasive fibrosis scores, and such effects could not be delineated. Systematic screening for other liver diseases was not performed; however, the prevalence of undiagnosed chronic liver diseases such as viral hepatitis [41] in the study population is likely to be low. We could not identify factors associated with improvement of liver fibrosis, and our finding should be validated in other patient cohorts.

5. Conclusions

This study of a RYGB cohort with a unique long-term follow-up of 11.6 years suggests that RYGB leads to resolution of NAFLD fibrosis in the majority of patients with high risk. Improvement of NAFLD and related fibrosis may be among the major benefits of RYGB, and there was no correlation with degree of weight loss or remission of T2DM. Therefore, we have not been able to identify any specific groups of patients who seem to benefit more from bariatric surgery. Considering the increasing rate of obesity globally, studies of NAFLD and fibrosis seem essential.

Author Contributions: Conceptualization, R.F., J.S. and D.A.L.H.; methodology, E.C.S.S., J.S., K.M.A. and R.F.; formal analysis, E.C.S.S. and R.F.; investigation, G.J., D.A.L.H., B.K., Å.A.H., H.G., S.N. and J.S.; data curation, J.S.; writing—original draft preparation, E.C.S.S.; writing—review and editing All authors; supervision, J.S. and R.F.; project administration, J.S. and R.F.; funding acquisition, J.S. and D.A.L.H. All authors have read and agreed to the published version of the manuscript.

Funding: The Liaison Committee for Education, Research and Innovation in Central Norway and Norwegian University of Science and Technology (NTNU) Norway, grant number 46055500. This study was founded by a grant from Møre and Romsdal Hospital Trust (Grant number P-101618-01).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Committee for Research Ethics approved the study (REK 2017/1828 south-east Norway B).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Due to ethical and legal regulations of clinical research, the data cannot be shared.

Acknowledgments: We would like to thank all participants for their time and commitment, and the staff at the Obesity out-patient clinic at Namsos hospital, the Centre for Obesity at St. Olav's hospital, Trondheim University Hospital, and the Clinical Research Unit, Møre & Romsdal Hospital trust, Ålesund, for invaluable effort in data collection.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Appendix A

Table A1. Patients with reduction of fibrosis scores vs. patients with increased scores 11.6 years after Roux-en-Y gastric bypass surgery.

Variable	FIB-4			NFS			
	Decrease (n = 97)	Increase (n = 123)	p Value	Decrease (n = 137)	Increase (n = 83)	p Value	
Age baseline, years, mean \pm SD	42.0 \pm 9.69	38.5 \pm 9.01	0.006	40.4 \pm 9.37	39.4 \pm 9.63	0.445	
Female n (%)	77 (79.4)	95 (77.2)	0.702	110 (80.3)	62 (74.7)	0.330	
BMI baseline, kg/m ² , median (IQR)	43.6 (40.2–45.8)	43.5 (40.5–48.2)	0.306	43.4 (40.6–46.8)	43.6 (40.2–47.3)	0.564	
BMI follow-up, kg/m ² , median (IQR)	33.7 (29.6–38.4)	32.9 (29.5–37.1)	0.280	33.3 (29.4–37.4)	33.1 (30.5–40.5)	0.260	
BMI Nadir, kg/m ² , median (IQR)	28.0 (26.0–32.0)	27.0 (25.0–30.0)	0.078	27.0 (25.0–31.5)	29.0 (26.0–31.0)	0.170	
%TWL, mean \pm SD	20.7 \pm 11.6	24.4 \pm 10.6	0.016	24.3 \pm 10.7	20.2 \pm 11.5	0.008	
%EWL, mean \pm SD	50.2 \pm 28.0	57.8 \pm 26.1	0.039	57.6 \pm 25.9	49.2 \pm 28.5	0.026	
T2DM baseline n (%)	17 (17.5)	23 (18.7)	0.823	30 (21.9)	10 (12.0)	0.073	
T2DM follow-up n (%)	12 (12.4)	11 (8.9)	0.409	12 (8.8)	11 (13.3)	0.364	
NFS baseline, median (IQR)	FIB-4 baseline, median (IQR)	–0.63 (–1.55–0.22)	–1.76 (–2.49––0.87)	>0.0001	0.96 (0.72–1.42)	0.65 (0.49–0.85)	>0.0001
NFS follow-up, median (IQR)	FIB-4 follow-up, median (IQR)	–1.85 (–2.65––0.97)	–1.61 (–2.33––0.92)	0.204	0.89 (0.69–1.12)	0.89 (0.69–1.20)	0.476

FIB-4, Fibrosis-4 index; NFS, non-alcoholic fatty liver disease fibrosis score; BMI, body mass index; %TWL, percentage total weight loss; %EWL, percentage excess weight loss; T2DM, type 2 diabetes mellitus; IQR, interquartile range; SD, standard deviation.

References

1. EASL–EASD–EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J. Hepatol.* **2016**, *64*, 1388–1402. [[CrossRef](#)]
2. Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. *J. Hepatol.* **2015**, *62*, S47–S64. [[CrossRef](#)]
3. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* **2016**, *64*, 73–84. [[CrossRef](#)]
4. Croci, I.; Coombes, J.S.; Bucher Sandbakk, S.; Keating, S.E.; Nauman, J.; Macdonald, G.A.; Wisloff, U. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. *Prog. Cardiovasc. Dis.* **2019**, *62*, 127–134. [[CrossRef](#)]
5. Holmer, M.; Melum, E.; Isoniemi, H.; Ericzon, B.-G.; Castedal, M.; Nordin, A.; Aagaard Schultz, N.; Rasmussen, A.; Line, P.-D.; Stål, P.; et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. *Liver Int.* **2018**, *38*, 2082–2090. [[CrossRef](#)]
6. Mitra, S.; De, A.; Chowdhury, A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. *Transl. Gastroenterol. Hepatol.* **2020**, *5*, 16. [[CrossRef](#)]
7. Piazzolla, V.A.; Mangia, A. Noninvasive Diagnosis of NAFLD and NASH. *Cells* **2020**, *9*, 1005. [[CrossRef](#)]
8. Kupčová, V.; Fedelešová, M.; Bulas, J.; Kozmonová, P.; Turecký, L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. *Int. J. Environ. Res. Public Health* **2019**, *16*, 3570. [[CrossRef](#)]
9. Xiao, G.; Zhu, S.; Xiao, X.; Yan, L.; Yang, J.; Wu, G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. *Hepatology* **2017**, *66*, 1486–1501. [[CrossRef](#)]
10. Ekstedt, M.; Hagström, H.; Nasr, P.; Fredrikson, M.; Stål, P.; Kechagias, S.; Hultcrantz, R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology* **2015**, *61*, 1547–1554. [[CrossRef](#)]
11. Lassailly, G.; Caiazzo, R.; Ntandja-Wandji, L.-C.; Gnemmi, V.; Baud, G.; Verkindt, H.; Ningarhari, M.; Louvet, A.; Leteurtre, E.; Raverdy, V.; et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. *Gastroenterology* **2020**, *159*, 1290–1301.e1295. [[CrossRef](#)]
12. Lee, Y.; Doumouras, A.G.; Yu, J.; Brar, K.; Banfield, L.; Gmora, S.; Anvari, M.; Hong, D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. *Clin. Gastroenterol. Hepatol.* **2019**, *17*, 1040–1060.e1011. [[CrossRef](#)]

13. Zhou, H.; Luo, P.; Li, P.; Wang, G.; Yi, X.; Fu, Z.; Sun, X.; Cui, B.; Zhu, L.; Zhu, S. Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. *Obes. Surg.* **2022**, *32*, 1872–1883. [[CrossRef](#)]
14. Rehm, J.; Taylor, B.; Mohapatra, S.; Irving, H.; Baliunas, D.; Patra, J.; Roerecke, M. Alcohol as a risk factor for liver cirrhosis: A systematic review and meta-analysis. *Drug Alcohol. Rev.* **2010**, *29*, 437–445. [[CrossRef](#)]
15. Mellinger, J.L.; Shedden, K.; Winder, G.S.; Fernandez, A.C.; Lee, B.P.; Waljee, J.; Fontana, R.; Volk, M.L.; Blow, F.C.; Lok, A.S.F. Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. *Liver Int.* **2021**, *41*, 1012–1019. [[CrossRef](#)]
16. Azam, H.; Shahrestani, S.; Phan, K. Alcohol use disorders before and after bariatric surgery: A systematic review and meta-analysis. *Ann. Transl. Med.* **2018**, *6*, 148. [[CrossRef](#)]
17. Lefere, S.; Onghena, L.; Vanlander, A.; van Nieuwenhove, Y.; Devisscher, L.; Geerts, A. Bariatric surgery and the liver—Mechanisms, benefits, and risks. *Obes. Rev.* **2021**, *22*, e13294. [[CrossRef](#)]
18. Berzigotti, A.; Tsochatzis, E.; Boursier, J.; Castera, L.; Cazzagon, N.; Friedrich-Rust, M.; Petta, S.; Thiele, M. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis—2021 update. *J. Hepatol.* **2021**, *75*, 659–689. [[CrossRef](#)]
19. Cheah, M.C.; McCullough, A.J.; Goh, G.B.-B. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. *J. Clin. Transl. Hepatol.* **2017**, *5*, 261–271. [[CrossRef](#)]
20. McPherson, S.; Hardy, T.; Dufour, J.F.; Petta, S.; Romero-Gomez, M.; Allison, M.; Oliveira, C.P.; Francque, S.; Van Gaal, L.; Schattenberg, J.M.; et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. *Am. J. Gastroenterol.* **2017**, *112*, 740–751. [[CrossRef](#)]
21. Losekann, A.; Weston, A.C.; De Mattos, A.A.; Tovo, C.V.; De Carli, L.A.; Espindola, M.B.; Pioner, S.R.; Coral, G.P. Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. *Int. J. Mol. Sci.* **2015**, *16*, 25552–25559.
22. Luger, M.; Kruschitz, R.; Kienbacher, C.; Traussnigg, S.; Langer, F.B.; Schindler, K.; Würger, T.; Wrba, F.; Trauner, M.; Prager, G.; et al. Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. *Obes. Surg.* **2016**, *26*, 2425–2432. [[CrossRef](#)]
23. Gholam, P.M.; Flancbaum, L.; Machan, J.T.; Charney, D.A.; Kotler, D.P. Nonalcoholic Fatty Liver Disease in Severely Obese Subjects. *Off. J. Am. Coll. Gastroenterol. ACG* **2007**, *102*, 399–408.
24. Ratziu, V.; Giral, P.; Charlotte, F.; Bruckert, E.; Thibault, V.; Theodorou, I.; Khalil, L.; Turpin, G.; Opolon, P.; Poynard, T. Liver fibrosis in overweight patients. *Gastroenterology* **2000**, *118*, 1117–1123. [[CrossRef](#)]
25. Klair, J.S.; Yang, J.D.; Abdelmalek, M.F.; Guy, C.D.; Gill, R.M.; Yates, K.; Unalp-Arida, A.; Lavine, J.E.; Clark, J.M.; Diehl, A.M.; et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. *Hepatology* **2016**, *64*, 85–91. [[CrossRef](#)]
26. Nascimento, T.M.; Alves-Júnior, A.; Nunes, M.A.; de Freitas, T.R.; da Silva, M.A.; Alves, M.R. Comparison of Hepatic Profile in Pre and Postoperative of Bariatric Surgery: Private vs. Public Network. *Arq. Bras. Cir. Dig.* **2015**, *28*, 274–277. [[CrossRef](#)]
27. Nickel, F.; Tapking, C.; Benner, L.; Sollors, J.; Billeter, A.T.; Kenngott, H.G.; Bokhary, L.; Schmid, M.; von Frankenberg, M.; Fischer, L.; et al. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up: BariScan Study. *Obes. Surg.* **2018**, *28*, 1342–1350. [[CrossRef](#)]
28. Toman, D.; Vávra, P.; Jelinek, P.; Ostruszka, P.; Ihnát, P.; Foltys, A.; Pelikan, A.; Roman, J. Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czechoslov.* **2021**, *166*, 195–203. [[CrossRef](#)]
29. Cazzo, E.; Jimenez, L.S.; Pareja, J.C.; Chaim, E.A. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: A prospective study. *Obes. Surg.* **2015**, *25*, 982–985. [[CrossRef](#)]
30. Agarwal, L.; Aggarwal, S.; Shalimar; Yadav, R.; Dattagupta, S.; Garg, H.; Agarwal, S. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan. *Obes. Surg.* **2021**, *31*, 617–626. [[CrossRef](#)]
31. Lassailly, G.; Caiazzo, R.; Buob, D.; Pigeyre, M.; Verkindt, H.; Labreuche, J.; Raverdy, V.; Leteurtre, E.; Dharancy, S.; Louvet, A.; et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. *Gastroenterology* **2015**, *149*, 379–388. [[CrossRef](#)]
32. Fakhry, T.K.; Mhaskar, R.; Schwitalla, T.; Muradova, E.; Gonzalvo, J.P.; Murr, M.M. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. *Surg. Obes. Relat. Dis.* **2019**, *15*, 502–511. [[CrossRef](#)]
33. Mummadi, R.R.; Kasturi, K.S.; Chennareddygari, S.; Sood, G.K. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **2008**, *6*, 1396–1402. [[CrossRef](#)]
34. Schmid, A.; Ariens, M.; Karrasch, T.; Pons-Kühnemann, J.; Schäffler, A.; Roderfeld, M.; Roeb, E. Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. *J. Clin. Med.* **2022**, *11*, 1756. [[CrossRef](#)]
35. Yeo, S.C.; Ong, W.M.; Cheng, K.S.A.; Tan, C.H. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. *Obes. Surg.* **2019**, *29*, 1295–1300. [[CrossRef](#)]
36. Głuszyńska, P.; Lemancewicz, D.; Dziecioł, J.B.; Razak Hady, H. Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. *J. Clin. Med.* **2021**, *10*, 5721. [[CrossRef](#)]
37. Laursen, T.L.; Hagemann, C.A.; Wei, C.; Kazankov, K.; Thomsen, K.L.; Knop, F.K.; Grønbæk, H. Bariatric surgery in patients with non-alcoholic fatty liver disease—From pathophysiology to clinical effects. *World J. Hepatol.* **2019**, *11*, 138–149. [[CrossRef](#)]

38. Abu-Gazala, S.; Horwitz, E.; Ben-Haroush Schyr, R.; Bardugo, A.; Israeli, H.; Hija, A.; Schug, J.; Shin, S.; Dor, Y.; Kaestner, K.H.; et al. Sleeve Gastrectomy Improves Glycemia Independent of Weight Loss by Restoring Hepatic Insulin Sensitivity. *Diabetes* **2018**, *67*, 1079–1085. [[CrossRef](#)]
39. Srivastava, A.; Stevenson, M.; Lee, J.; Hall, C.; Palaia, T.; Zhao, C.L.; Lau, R.; Brathwaite, C.; Ragolia, L. Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet. *Obes. Surg.* **2022**, *32*, 2010–2022. [[CrossRef](#)]
40. Ahmed, S.; Pouwels, S.; Parmar, C.; Kassir, R.; de Luca, M.; Graham, Y.; Mahawar, K. Outcomes of Bariatric Surgery in Patients with Liver Cirrhosis: A Systematic Review. *Obes. Surg.* **2021**, *31*, 2255–2267. [[CrossRef](#)]
41. Norwegian Surveillance System for Communicable Diseases (MSIS). Available online: <http://www.msis.no/> (accessed on 16 May 2022).